Content about GSK

April 22, 2014

Following a multifaceted deal with Novartis on Tuesday, GlaxoSmithKline and Novartis have created a consumer healthcare giant with annual worldwide revenues of $11 billion on a 2013 pro forma basis.

LONDON — Following a multifaceted deal with Novartis on Tuesday, GlaxoSmithKline and Novartis have created a consumer healthcare giant with annual worldwide revenues of $11 billion on a 2013 pro forma basis. The new business, to be called GSK Consumer Healthcare, will hold category leading positions and brands in wellness, oral health, nutrition and skin health, the company reported.

April 22, 2014

Novartis on Tuesday made a number of moves that have fundamentally reshaped its business, according to published reports.

ZURICH — Novartis on Tuesday made a number of moves that have fundamentally reshaped its business, according to published reports. Novartis exchanged its vaccine business with GlaxoSmithKline in a deal valued at $7.1 billion for GSK's oncology portfolio (at a cost of $14.5 billion) and divested its animal health unit to Ely Lilly for approximately $5.4 billion. 

July 23, 2013

A federal court has ruled that a Mylan lawsuit against GlaxoSmithKline over an antidepressant drug can go to trial.

PITTSBURGH — A federal court has ruled that a Mylan lawsuit against GlaxoSmithKline over an antidepressant drug can go to trial, Mylan said Tuesday.

Mylan alleges that GlaxoSmithKline breached a contract the two companies had made when it agreed to supply competing drug maker Apotex with paroxetine hydrochloride extended-release tablets, a generic version of Paxil CR. The Third Circuit Court of Appeals' ruling reversed a summary judgment dismissing Mylan's claim.

November 8, 2012

GlaxoSmithKline on Thursday announced the five recipients of its annual GlaxoSmithKline IMPACT Awards.

RESEARCH TRIANGLE PARK, N.C. — GlaxoSmithKline on Thursday announced the five recipients of its annual GlaxoSmithKline IMPACT Awards. In total, the North Carolina and Philadelphia-area healthcare nonprofit organizations will receive $200,000 in grant funding ($40,000 each) for providing access to healthcare for the underserved in their communities.

November 5, 2012

The opportunity for weight loss certainly hasn’t gone away — sales of diet-aid liquids were up 12.8% to $1.2 billion for the 52 weeks ended Sept. 9 across food, drug and mass (excluding Walmart), according to SymphonyIRI.

The opportunity for weight loss certainly hasn’t gone away — sales of diet-aid liquids were up 12.8% to $1.2 billion for the 52 weeks ended Sept. 9 across food, drug and mass (excluding Walmart), according to SymphonyIRI. And due to the temporary absence of GlaxoSmithKline’s Alli — unavailable because of a raw-ingredient sourcing issue — sales of diet-aid tablets are down with a 7% decline to a dollar base of 
$205.4 million. 
Alli had been removed from the market in March due to the third-party supply issue and returned in late June. 


May 21, 2012

The U.S. subsidiary of British drug maker GlaxoSmithKline and U.S.-based Auxilium Pharmaceuticals will co-promote a testosterone-replacement drug, the two said Monday.

MALVERN, Pa. — The U.S. subsidiary of British drug maker GlaxoSmithKline and U.S.-based Auxilium Pharmaceuticals will co-promote a testosterone-replacement drug, the two said Monday.

GSK and Auxilium announced an agreement for the co-promotion of Testim 1% (testosterone gel), used in men with conditions related to deficiency or absence of the hormone.

May 17, 2012

Prestige Brands closed out its fiscal 2012 ended March 31 on a high note with $441.1 million in revenues for the year, up 31.1%. And fiscal 2013 is looking promising as the company will have full-year contributions from its 17 acquired over-the-counter brands from GlaxoSmithKline.

IRVINGTON, N.Y. — Prestige Brands closed out its fiscal 2012 ended March 31 on a high note with $441.1 million in revenues for the year, up 31.1%. And fiscal 2013 is looking promising as the company will have full-year contributions from its 17 acquired over-the-counter brands from GlaxoSmithKline.

June 14, 2011

GlaxoSmithKline has garnered strong interest in its portfolio of legacy brands that were placed on the sales block earlier this year, according to a Reuters report published Tuesday. And that interest is likely to pick up in the coming months, GSK CEO Andrew Witty told reporters during a meeting of pharmaceutical industry executives.

BRUSSELS — GlaxoSmithKline has garnered strong interest in its portfolio of legacy brands that were placed on the sales block earlier this year, according to a Reuters report published Tuesday. And that interest is likely to pick up in the coming months, GSK CEO Andrew Witty told reporters during a meeting of pharmaceutical industry executives.

The interest is coming from both established consumer healthcare companies, as well as private equity houses, the report noted.

April 14, 2011

GlaxoSmithKline on Thursday identified the remaining noncore over-the-counter brands that it intends to divest as the company focuses its Consumer Healthcare business around a portfolio of fast-growing priority brands and emerging markets.

LONDON — GlaxoSmithKline on Thursday identified the remaining noncore over-the-counter brands that it intends to divest as the company focuses its Consumer Healthcare business around a portfolio of fast-growing priority brands and emerging markets.

GSK said it planned to contact companies interested in acquiring the brands over the next few weeks and expected to complete all divestitures by late 2011.

April 12, 2011

Darren Singer, a 25-year GlaxoSmithKline veteran, has been named Safeway's SVP pharmacy, health and wellness, the retailer announced.

PLEASANTON, Calif. — Darren Singer, a 25-year GlaxoSmithKline veteran, has been named Safeway's SVP pharmacy, health and wellness, the retailer announced.

Singer will be responsible for retail pharmacy operations, specialty care, pharmacy services, compliance, benefit management and managed care for Safeway. He will report to Safeway's merchandising president, Kelly Griffith.

March 11, 2011

GlaxoSmithKline said it is establishing a dedicated team to support community pharmacists and other healthcare professionals.

RESEARCH TRIANGLE PARK, N.C. — GlaxoSmithKline said it is establishing a dedicated team to support community pharmacists and other healthcare professionals.

Effective March 28, GSK said its community pharmacy liaisons will provide information and tools to help community pharmacists communicate with their patients about chronic diseases and the appropriate use of medicines and vaccines.

February 3, 2011

Drug maker Valeant Pharmaceuticals International has acquired U.S. and Canadian rights to certain formulations of a GlaxoSmithKline drug used to treat cold sores.

MISSISSAUGA, Ontario — Drug maker Valeant Pharmaceuticals International has acquired U.S. and Canadian rights to certain formulations of a GlaxoSmithKline drug used to treat cold sores.

Valeant announced Thursday that it had acquired the rights to nonophthalmic topical formulations of Zovirax (acyclovir) from GSK for $300 million through its Canadian subsidiary, Biovail Labs.

June 6, 2010

GlaxoSmithKline in April announced the launch of its new Nicorette Mini Lozenge, a smaller smoking...

PARSIPPANY, N.J. —GlaxoSmithKline in April announced the launch of its new Nicorette Mini Lozenge, a smaller smoking cessation lozenge that dissolves three times faster than stop-smoking lozenges currently on the market. The lozenges will be line-priced with existing smoking cessation products and will be sold as three small vials each containing 27 lozenges.